Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$39.77 USD
+0.95 (2.45%)
Updated May 7, 2024 04:00 PM ET
After-Market: $39.54 -0.23 (-0.58%) 6:46 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
CRBP 39.77 +0.95(2.45%)
Will CRBP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRBP
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
Other News for CRBP
CRBP Stock Earnings: Corbus Pharmaceuticals Beats EPS for Q1 2024
Corbus Pharmaceuticals EPS of -$0.83 beats by $0.26
Corbus Pharmaceuticals: Q1 Earnings Snapshot
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Financial Performance Update Insights